{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:56Z","timestamp":1761870536624,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clml.2012.11.009","type":"journal-article","created":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T03:36:13Z","timestamp":1356147373000},"page":"292-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Asifa","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahran","family":"Shoukier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.11.009_bib1","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2011-01-329177","article-title":"Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia","volume":"118","author":"Parikh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.009_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.11.009_bib3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(11)70242-X","article-title":"Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial","volume":"12","author":"Elter","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2012.11.009_bib4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood-2011-03-341032","article-title":"Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.009_bib5","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.009_bib6","first-page":"1078","article-title":"ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia","volume":"90","author":"Corcoran","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.11.009_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2007.03.043","article-title":"Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia","volume":"129","author":"Raval","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.clml.2012.11.009_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4161\/epi.5.6.12179","article-title":"Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact","volume":"5","author":"Tong","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.clml.2012.11.009_bib9","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.009_bib10","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.009_bib11","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.009_bib12","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-08-1247","article-title":"Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers","volume":"14","author":"Braiteh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.11.009_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.2010.08213.x","article-title":"Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation","volume":"150","author":"Blum","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:05Z","timestamp":1761870245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S2152265012002546"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}